Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Pharmosa Biopharm Inc.

Clinicaltrial registered9 Nov 2026

Pharmosa Biopharm Inc.

9 Nov 2026: Trial registered · Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
9 Nov 2026
Title
Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers
Conditions
Systemic Sclerosis
Phase
Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07925619
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Pharmosa Biopharm Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.